AI Drug Discovery Beyond the Semiconductor Crowd
AI discovery platforms are being re-rated as capital looks past chips into actual drug pipelines.
Antibody and multimodal clinical-data platforms can compress discovery timelines and win more partnered programs. Recent sharp upside in the group shows the theme is already attracting capital, while names with large proprietary datasets still screen cheap versus semiconductor AI peers.
| Instrument | Side | Target | Reason |
|---|---|---|---|
| ABCL | Long | AbCellera's antibody-discovery engine can generate and screen candidates faster than traditional wet-lab cycles, so the platform should capture a rising share of partnered programs as pharma outsources AI-native discovery. | |
| TEM | Long | Tempus owns a large multimodal clinical and molecular dataset, and the Microsoft partnership can scale distribution and compute, so the shares still underprice the data moat relative to other AI compounders. |
Eli Lilly can compound from a $1.1T franchise toward a multi-trillion AI-enabled drug-discovery leader.
Lilly already compounds through a dominant metabolic franchise and can use AI to refill and broaden the pipeline. That combination supports a path from roughly $1.1T toward a $4T drug-discovery platform rather than a single-product obesity story.
| Instrument | Side | Target | Reason |
|---|---|---|---|
| LLY | Long | Scale, cash flow, and AI-accelerated discovery give Lilly a realistic path from a $1.1T valuation toward a $4T drug-discovery leader as the pipeline broadens beyond today's metabolic winners. |
Themes
The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.